Acelyrin

Acelyrin is a company listed under the stock ticker ACELYRIN (US).

View the org chart displaying its 22 main executives

Most searched biographies at Acelyrin

• Mina Kim, Chief Executive Officer and Director
• Henry Gosebruch, Director
• Alan Colowick, Director

Popular executive movements at Acelyrin

• Shao-Lee Lin, Chief Executive Officer and Director, has left the company  (posted on May 10 2024).
• Mina Kim, who was Chief Legal and Administrative Officer, is promoted to Chief Executive Officer and Director  (posted on May 10 2024).
• Agnes Lee has joined the company as Senior Vice President, Investor Relations and Corporate Communications  (posted on February 16 2024).

Click here to view some more movements at Acelyrin

Create your alert
to follow the executive moves at Acelyrin.

Acelyrin has 2,297 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Grey Wolf Therapeutics has just announced a $50 Million fundraising (posted on May 25 2024).
• AbbVie has acquired Landos Biopharma (posted on May 25 2024).
• AltruBio has just announced a $225 Million fundraising (posted on May 24 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Acelyrin

• An interview with ACELYRIN’s Chief Operating Officer Melanie Gloria
• News Center | ACELYRIN
• Shao-Lee Lin, MD, PhD - Courageous Caring in the Age of COVID
• Dr. Shao-Lee Lin and Bob Carey talk strategy and more at ACELYRIN
• ACELYRIN | An Innovative Biopharma Company
• Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
• ACELYRIN, INC. Adds Two Veteran C-suite Leaders
• ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Funct
• ACELYRIN, INC. to Present at Upcoming Investor Conferences
• ACELYRIN | $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep
• View more press releases Close

Social media about Acelyrin

• Acelyrin on Wikipedia, Google News & Yahoo Finance
• Acelyrin on LinkedIn, Twitter & YouTube

Contact by email its executives including Mina Kim

Call Acelyrin at +1 310...

View the org chart

Register to receive your alert

Report an error